Literature DB >> 32116086

Long noncoding RNA LINC00657 enhances the malignancy of pancreatic ductal adenocarcinoma by acting as a competing endogenous RNA on microRNA-433 to increase PAK4 expression.

Shasha Bi1, Yan Wang1,2, Hu Feng3, Qingchang Li1,2.   

Abstract

A long noncoding RNAs (lncRNA) called LINC00657 is dysregulated and contributes to tumor progression in a number of human cancer types. However, there is limited information on the expression profile and functions of LINC00657 in pancreatic ductal adenocarcinoma (PDAC). The expression profile of LINC00657 in PDAC was estimated by reverse-transcription quantitative polymerase chain reaction (RT-qPCR). The effects of LINC00657 upregulation on PDAC cell proliferation, apoptosis, migration, and invasion in vitro and tumor growth in vivo were explored using CCK-8, flow cytometry, Transwell migration and invasion assays, and a xenograft tumor formation experiment, respectively. The results revealed that LINC00657 was evidently upregulated in the PDAC tumors and cell lines. High LINC00657 expression significantly correlated with the pathological T stage, lymph node metastasis, and shorter overall survival. Functional analysis demonstrated that LINC00657 knockdown inhibited the proliferation, migration, and invasion while promoted the apoptosis of PDAC cells. In addition, LINC00657 knockdown markedly suppressed tumor growth of these cells in vivo. In terms of the mechanism, LINC00657 could directly interact with microRNA-433 (miR-433) and effectively worked as an miR-433 sponge, thus decreasing the competitive binding of miR-433 to PAK4 mRNA and ultimately increasing PAK4 expression. The actions of LINC00657 knockdown on malignant phenotype of PDAC cells were strongly attenuated by miR-433 inhibition and PAK4 restoration. These results indicate that LINC00657 promotes PDAC progression by increasing the output of the miR-433-PAK4 regulatory loop, thus highlighting the importance of the LINC00657-miR-433-PAK4 network in PDAC pathogenesis.

Entities:  

Keywords:  LINC00657; PAK4; microRNA-433; pancreatic ductal adenocarcinoma; target therapy

Year:  2020        PMID: 32116086      PMCID: PMC7145330          DOI: 10.1080/15384101.2020.1731645

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  46 in total

1.  Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.

Authors:  Amro Aboukameel; Irfana Muqbil; William Senapedis; Erkan Baloglu; Yosef Landesman; Sharon Shacham; Michael Kauffman; Philip A Philip; Ramzi M Mohammad; Asfar S Azmi
Journal:  Mol Cancer Ther       Date:  2016-11-15       Impact factor: 6.261

Review 2.  Competitive endogenous RNA in colorectal cancer: A systematic review.

Authors:  Han Shuwen; Zhou Qing; Zheng Yan; Yang Xi
Journal:  Gene       Date:  2017-12-19       Impact factor: 3.688

3.  Prioritization of non-coding disease-causing variants and long non-coding RNAs in liver cancer.

Authors:  Hua Li; Zekun He; Yang Gu; Lin Fang; Xin Lv
Journal:  Oncol Lett       Date:  2016-09-14       Impact factor: 2.967

4.  Long non-coding RNA 657 suppresses hepatocellular carcinoma cell growth by acting as a molecular sponge of miR-106a-5p to regulate PTEN expression.

Authors:  Bingren Hu; Huajie Cai; Ru Zheng; Shouzhang Yang; Zhenxu Zhou; Jinfu Tu
Journal:  Int J Biochem Cell Biol       Date:  2017-09-14       Impact factor: 5.085

5.  Molecular profiling of platinum resistant ovarian cancer.

Authors:  Jozien Helleman; Maurice P H M Jansen; Paul N Span; Iris L van Staveren; Leon F A G Massuger; Marion E Meijer-van Gelder; Fred C G J Sweep; Patricia C Ewing; Maria E L van der Burg; Gerrit Stoter; Kees Nooter; Els M J J Berns
Journal:  Int J Cancer       Date:  2006-04-15       Impact factor: 7.396

Review 6.  Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.

Authors:  Rosella Spadi; Federica Brusa; Agostino Ponzetti; Isabella Chiappino; Nadia Birocco; Libero Ciuffreda; Maria Antonietta Satolli
Journal:  World J Clin Oncol       Date:  2016-02-10

7.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

Review 8.  Role of non-coding RNA in pancreatic cancer.

Authors:  Yinghao Lv; Shuai Huang
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

9.  MicroRNA-448 suppresses metastasis of pancreatic ductal adenocarcinoma through targeting JAK1/STAT3 pathway.

Authors:  Dan-Li Yu; Tao Zhang; Kun Wu; Yan Li; Juan Wang; Jun Chen; Xiao-Quan Li; Xing-Guo Peng; Jia-Ning Wang; Li-Guo Tan
Journal:  Oncol Rep       Date:  2017-07-03       Impact factor: 4.136

10.  Long noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinoma.

Authors:  Yalu Zhang; Rundong Zhang; Guopei Luo; Kaixing Ai
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

View more
  8 in total

1.  Circ-MBOAT2 knockdown represses tumor progression and glutamine catabolism by miR-433-3p/GOT1 axis in pancreatic cancer.

Authors:  Xiaoxiao Zhou; Kun Liu; Jing Cui; Jiongxin Xiong; Heshui Wu; Tao Peng; Yao Guo
Journal:  J Exp Clin Cancer Res       Date:  2021-04-08

2.  LncRNA LINC00857 strengthens the malignancy behaviors of pancreatic adenocarcinoma cells by serving as a competing endogenous RNA for miR-340-5p to upregulate TGFA expression.

Authors:  Tingfu Li; Hongbo Zhao; Hua Zhou; Tingting Geng
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

3.  NSE, positively regulated by LINC00657-miR-93-5p axis, promotes small cell lung cancer (SCLC) invasion and epithelial-mesenchymal transition (EMT) process.

Authors:  Lin Lu; Zhiqiang Zha; Peiling Zhang; Dailing Li; Guolong Liu
Journal:  Int J Med Sci       Date:  2021-10-15       Impact factor: 3.738

Review 4.  Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer.

Authors:  Lorenzo F Sempere; Katherine Powell; Jatin Rana; Andrew A Brock; Thomas D Schmittgen
Journal:  Cancer Metastasis Rev       Date:  2021-09-30       Impact factor: 9.264

Review 5.  Regulatory Roles of Noncoding RNAs in the Progression of Gastrointestinal Cancers and Health Disparities.

Authors:  Aditi Kulkarni; Sharan Gayathrinathan; Soumya Nair; Anamika Basu; Taslim A Al-Hilal; Sourav Roy
Journal:  Cells       Date:  2022-08-07       Impact factor: 7.666

Review 6.  The role of MiRNA-433 in malignant tumors of digestive tract as tumor suppressor.

Authors:  Jie Tang; Jiawei Chen; Yongqiang Wang; Shaobo Zhou
Journal:  Cancer Rep (Hoboken)       Date:  2022-08-17

Review 7.  Regulation of Hippo, TGFβ/SMAD, Wnt/β-Catenin, JAK/STAT, and NOTCH by Long Non-Coding RNAs in Pancreatic Cancer.

Authors:  Ammad Ahmad Farooqi; Sawera Nayyab; Chiara Martinelli; Rossana Berardi; Hector Katifelis; Maria Gazouli; William C Cho
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

8.  Knockdown of lncRNA ABHD11-AS1 Suppresses the Tumorigenesis of Pancreatic Cancer via Sponging miR-1231.

Authors:  Bowei Liu; Wei Wang; Suofeng Sun; Hui Ding; Ling Lan; Xiuling Li; Shuangyin Han
Journal:  Onco Targets Ther       Date:  2020-11-05       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.